Erica Mazzola

Network Positions and the Probability of Being Acquired: An Empirical Analysis in the Biopharmaceutical Industry

This paper examines the relationship between the firms direct ties, its inter-firm network prominence and its likelihood of being acquired. The authors argue that firms direct ties and prominence enhance the firms visibility and signal its quality – and thus foster the firms likelihood of being acquired. However, higher levels of direct ties and prominence, by providing access to resources and the firms status, respectively, increase the firms ability to remain independent and thus reduce its likelihood of being acquired. Thus, the authors posit the overall relation as an inverted U-shaped. Furthermore, they show that, for firms that undergo an initial public offering, the aforementioned relation becomes much weaker. The hypotheses are empirically tested in the biopharmaceutical industry and important theoretical and managerial implications are discussed.

How the purpose of the inter-firm relationships influences the choice of the governance form: evidence from the machine tool and the pharmaceutical industries

In todays competitive landscape, the choice of the appropriate mode to govern an inter-firm relationship is a critical factor for companies. In the literature several theoretical strands have examined the impact of the purpose of inter-firm relationships on the forms of governance. Building on a robust literature review on the topic, this study focuses on a specific issue influencing the choice of the form of governance in inter-firm relationships, i.e. the purpose of inter-firm relationships with relation to partners resources. We gather in a unique framework three typologies of partners resources, i.e. production, R&D and marketing, and through two empirical analyses in two different Italian industries, machine tool and pharmaceutical, we show how differently these purposes shape the choice of the governance mode.

Collaboration experience in the supply chain of knowledge and patent development

Abstract In this paper, we aim at understanding the role of collaboration experience in supply chains of knowledge (SCoK). The SCoK of a company is its supply chain not related to the flow of physical goods but to the flow of R&D commodities. R&D commodities are for example patents, technologies, research services, studies, and projects, and, in high-tech industries, their development and commercialisation are considered as important as real products. To accomplish our aim in this paper, we fulfil the following research objectives: (1) investigate the relationship between the collaboration experience in SCoK and the propensity of the firm to develop new patents; (2) examine how the structural embeddedness of the firm within its SCoK mediates this relationship. We ground our conceptual model on the supply chain, open innovation and social capital literatures and empirically test our hypotheses on a cross-sectional data-set of 208 biotech companies that have signed 612 SCoK agreements in the years 2006–2010. The key findings of this study are: first, accumulating experience in SCoK collaborations facilitates the development of new patents; second, being central and bridging structural holes within the SCoK are two means by which the experience in SCoK collaborations is translated into new patents.

The magnitude of a product recall: offshore outsourcing vs. captive offshoring effects

The escalation in product recalls in recent years is attributed to the rise of globalisation and associated challenges of offshoring. Extant SCM research suggests that product recalls have a significant negative impact on financial performance, but gaps exist relative to the managerial actions to minimise their impact. Recall response strategies have become more important in the press, given that a single recall may result in the mandatory withdrawal of millions of products from the market, with firms incurring enormous logistics costs and brand damage. In this study, we address this gap in the research, and using a measure of product recall defined as the volume of products withdrawn from the market due to product quality failure. We explore the scale of the recall in the context of pharmaceutical sector global sourcing strategies, exploring whether the variation in global sourcing decisions not only increases the likelihood of a recall, but also influences the capability to minimise the total cost of recall. Our results suggest that offshore outsourcing and captive offshoring have opposite effects in terms of their influence on the magnitude of product recall. We summarise the implications through a compelling set of insights for future global sourcing strategy research themes.